Company Filing History:
Years Active: 1998-1999
Title: Ray S. Chang: Innovator in Peptide Research
Introduction
Ray S. Chang is a notable inventor based in Colma, California, recognized for his contributions to peptide research. He holds a total of 3 patents that focus on peptides that bind to the erythropoietin receptor, which have significant implications in medical science.
Latest Patents
Chang's latest patents include innovative peptides that bind to the erythropoietin receptor (EPO-R). These peptides consist of 10 to 40 or more amino acid residues in length, with a specific sequence that includes various amino acids. The first patent details peptides with the sequence X3X4X5GPX6TWX7X8 (SEQ ID NO:252), where each amino acid is represented by its standard one-letter abbreviation. The second patent outlines methods of administering these peptides, emphasizing their role as EPO agonists.
Career Highlights
Ray S. Chang is currently associated with Affymax Technologies, N.V., where he continues to advance his research in peptide technology. His work has contributed to the understanding of how these peptides can activate the erythropoietin receptor, potentially leading to new therapeutic applications.
Collaborations
Chang has collaborated with notable colleagues, including Nicholas C. Wrighton and William J. Dower, enhancing the research and development of peptide-based innovations.
Conclusion
Ray S. Chang's work in peptide research exemplifies the innovative spirit of modern science. His patents and ongoing research hold promise for advancements in medical treatments related to erythropoietin receptor activation.